Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

Completed · Phase 2

Conditions studied: Leukemia, T-Cell

In brief

BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced T-cell leukemia. Patients will receive an infusion of BCX-1777 on days 1-5. Treatment may be repeated every week for up to six courses. Patients are not required to be hospitalized for the administration of BCX-1777. Some patients may continue to receive an infusion of BCX-1777 twice a week for 6 weeks.

Key facts

Study ID

NCT00095381

Run by

BioCryst Pharmaceuticals

People needed

20

Starts

2004-03-01

Expected to finish

2007-12-01

Last updated by the study team

2012-01-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented T-cell leukemia (precursor T-lymphoblastic leukemia/lymphomia or T-PLL)
• Failure to have responded to one or more standard regimens for their disease.
• Performance status of <=2 by Eastern Cooperative Oncology Group (ECOG) criteria
• All ages are eligible
• Life expectancy of at least 3 months
• Adequate liver function (aspartate transaminase [AST] and/or alanine transaminase [ALT] not >3 times upper limits or normal [ULN])
• Adequate kidney function (calculated creatinine clearance >50 mL/min)
• Negative urine pregnancy test within 2 to 7 days prior to the start of study treamtment in females of childbearing potential
• Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study
• Signed informed consent/assent form (ICF) prior to start of any study specific procedures

You may not qualify if…

• Patients with known HIV infection or human T-cell leukemia virus type (HTLV-1)
• Patients with known Hepatitis B and/or Hepatitis C active infection
• Patients with active CMV infection
• Tumor-related central nervous system (CNS) leukemia requiring active treatment
• Active serious infection not controlled by oral or IV antibiotics
• Treatment with any investigational anti-leukemic agent or chemotherapy agent within 7 days prior to study entry, unless full recovery from side effects has occurred.
• Rapidly progressive disease with compromised organ function judged to be life-threatening by the investigator
• Concurrent treatment with other anticancer agents (corticosteroid use will not be excluded, but patient must remain on the stable dose)
• Cutaneous T-cell lymphoma (CTCL) diagnosis (including Sezary Syndrome)
• Pregnant and/or lactating women

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Palo Alto, California, United States
• Study site — Denver, Colorado, United States
• Study site — Gainesville, Florida, United States
• Study site — Lecanto, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Chicago, Illinois, United States
• Study site — Kansas City, Kansas, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Detroit, Michigan, United States
• Study site — Rolla, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Omaha, Nebraska, United States
• Study site — Hackensack, New Jersey, United States
• Weil Medical College of Cornell University — New York, New York, United States
• Study site — New York, New York, United States
• Study site — Syracuse, New York, United States
• Study site — The Bronx, New York, United States
• Study site — Spartanburg, South Carolina, United States
• Study site — Austin, Texas, United States
• Study site — Houston, Texas, United States
• Study site — Abingdon, Virginia, United States
• Study site — Tbilisi, Georgia, Georgia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.